CR20230052A - Combinaciones para el tratamiento de cáncer. - Google Patents
Combinaciones para el tratamiento de cáncer.Info
- Publication number
- CR20230052A CR20230052A CR20230052A CR20230052A CR20230052A CR 20230052 A CR20230052 A CR 20230052A CR 20230052 A CR20230052 A CR 20230052A CR 20230052 A CR20230052 A CR 20230052A CR 20230052 A CR20230052 A CR 20230052A
- Authority
- CR
- Costa Rica
- Prior art keywords
- combinations
- compound
- relates
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a combinaciones que comprenden un inhibidor de punto de control y un inhibidor de c-Met, el Compuesto 1. La invención también se refiere a formas cristalinas de la base libre del Compuesto 1, así como también formas cristalinas de sales del Compuesto 1, en combinación con un inhibidor de punto de control. La invención también se refiere una composición farmacéutica que comprende estas combinaciones. La invención además se refiere a métodos para tratar un cáncer administrando el Compuesto 1 como un agente único o una combinación descrita en este documento.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063059601P | 2020-07-31 | 2020-07-31 | |
US202063113556P | 2020-11-13 | 2020-11-13 | |
US202163148921P | 2021-02-12 | 2021-02-12 | |
PCT/US2021/043699 WO2022026706A1 (en) | 2020-07-31 | 2021-07-29 | Combinations for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230052A true CR20230052A (es) | 2023-04-11 |
Family
ID=77431400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230052A CR20230052A (es) | 2020-07-31 | 2021-07-29 | Combinaciones para el tratamiento de cáncer. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230301979A1 (es) |
EP (1) | EP4188376A1 (es) |
JP (1) | JP2023536264A (es) |
KR (1) | KR20230059792A (es) |
CN (1) | CN116437954A (es) |
AU (1) | AU2021318134A1 (es) |
BR (1) | BR112023001792A2 (es) |
CA (1) | CA3186517A1 (es) |
CL (1) | CL2023000289A1 (es) |
CO (1) | CO2023001561A2 (es) |
CR (1) | CR20230052A (es) |
IL (1) | IL300151A (es) |
MX (1) | MX2023001298A (es) |
PE (1) | PE20231369A1 (es) |
TW (1) | TW202220654A (es) |
WO (1) | WO2022026706A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20230287A (es) * | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
WO2023172917A1 (en) * | 2022-03-07 | 2023-09-14 | Sanofi-Aventis U.S. Llc | Use of isatuximab in combination with other agents for the treatment of multiple myeloma |
WO2023196899A2 (en) * | 2022-04-08 | 2023-10-12 | Global Cancer Technology | Methods and products to screen and treat glioblastoma multiforme and other cancers, including breast cancers, using a combination of pi3kinase inhibitors with checkpoint inhibitors |
CN117285533B (zh) * | 2023-11-24 | 2024-01-30 | 四川省医学科学院·四川省人民医院 | CD47/SIRPα小分子抑制剂及其应用和抗肿瘤药物组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
EP2992017B1 (en) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
CA3038500A1 (en) * | 2016-09-27 | 2018-04-05 | Andrea B. Apolo | Method of treating urothelial carcinoma and other genitourinary malignancies using n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
WO2018136796A1 (en) * | 2017-01-20 | 2018-07-26 | Exelixis, Inc. | Combinations of cabozantinib and atezolizumab to treat cancer |
CR20230287A (es) * | 2018-01-26 | 2023-07-26 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-358) |
JP2022512399A (ja) | 2018-12-13 | 2022-02-03 | エグゼリクシス, インコーポレイテッド | キナーゼ阻害剤の結晶性形態及び塩形態 |
-
2021
- 2021-07-29 US US18/018,805 patent/US20230301979A1/en active Pending
- 2021-07-29 AU AU2021318134A patent/AU2021318134A1/en active Pending
- 2021-07-29 JP JP2023506226A patent/JP2023536264A/ja active Pending
- 2021-07-29 CA CA3186517A patent/CA3186517A1/en active Pending
- 2021-07-29 CR CR20230052A patent/CR20230052A/es unknown
- 2021-07-29 BR BR112023001792A patent/BR112023001792A2/pt unknown
- 2021-07-29 IL IL300151A patent/IL300151A/en unknown
- 2021-07-29 WO PCT/US2021/043699 patent/WO2022026706A1/en active Application Filing
- 2021-07-29 EP EP21758525.6A patent/EP4188376A1/en active Pending
- 2021-07-29 KR KR1020237006875A patent/KR20230059792A/ko unknown
- 2021-07-29 PE PE2023000162A patent/PE20231369A1/es unknown
- 2021-07-29 MX MX2023001298A patent/MX2023001298A/es unknown
- 2021-07-29 CN CN202180065378.8A patent/CN116437954A/zh active Pending
- 2021-07-30 TW TW110128221A patent/TW202220654A/zh unknown
-
2023
- 2023-01-30 CL CL2023000289A patent/CL2023000289A1/es unknown
- 2023-02-14 CO CONC2023/0001561A patent/CO2023001561A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023000289A1 (es) | 2023-09-01 |
JP2023536264A (ja) | 2023-08-24 |
CN116437954A (zh) | 2023-07-14 |
MX2023001298A (es) | 2023-02-22 |
IL300151A (en) | 2023-03-01 |
US20230301979A1 (en) | 2023-09-28 |
AU2021318134A1 (en) | 2023-03-02 |
CA3186517A1 (en) | 2022-02-03 |
WO2022026706A1 (en) | 2022-02-03 |
PE20231369A1 (es) | 2023-09-07 |
KR20230059792A (ko) | 2023-05-03 |
EP4188376A1 (en) | 2023-06-07 |
BR112023001792A2 (pt) | 2023-04-11 |
TW202220654A (zh) | 2022-06-01 |
CO2023001561A2 (es) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001298A (es) | Combinaciones para el tratamiento de cancer. | |
ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
CR20220363A (es) | Compuestos tricíclicos sustituidos | |
MX2023007192A (es) | Inhibidores de prmt5. | |
MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
TW200639159A (en) | Treatment of pain | |
BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
AR060089A1 (es) | Tratamiento del dolor | |
BR0309342A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
MX2021010106A (es) | Inhibidores de la via de respuesta al estres integrada. | |
CR20210460A (es) | Compuestos útiles en la terapia del vih | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
ZA202006072B (en) | Ret inhibitor for use in treating cancer having a ret alteration | |
PH12021550832A1 (en) | Combination of small molecule cd-47 inhibitors with other anti-cancer agents | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
MX2022015813A (es) | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. | |
MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
MX2023006677A (es) | Composiciones para tratar la degeneracion macular seca relacionada con la edad (dme). | |
MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
MX2010002679A (es) | Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana. | |
MX2019011558A (es) | Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
RU2007143434A (ru) | 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний | |
MX2022015400A (es) | Uso del inhibidor de la fosfodiesterasa a 10 para el tratamiento del sindrome de tourette. | |
PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
BR112023016459A2 (pt) | Métodos terapêuticos |